2025 Net Income Plunges 97.7%, Operating Profit Down 66.3%
-
2025 sales: 264.1B KRW (+10.7%), operating profit: 3.5B KRW (-66.3%), net income: 0.1B KRW (-97.7%)
-
Reason for profit drop: increased investment in new facilities and R&D
-
Total assets: 319.2B, liabilities: 173.8B, equity: 145.4B
-
Unaudited, subject to change
KOSPI Filing Information
-
Filing: Change in Sales or Profit Structure of 30% (15% for Large Corporations) or More
-
Company: Kyongbo Pharmaceutical (214390)
-
Submission: Kyongbo Pharmaceutical Co., Ltd.
-
Receipt: 02-02-2026
-
Under KRX KOSPI Market Division